Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Gains from Sales and Divestitures (2020 - 2025)

Xtant Medical Holdings has reported Gains from Sales and Divestitures over the past 6 years, most recently at $1.2 million for Q3 2025.

  • Quarterly Gains from Sales and Divestitures fell 22.08% to $1.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Sep 2025, down 22.08% year-over-year, with the annual reading at $1.3 million for FY2024, 14.67% down from the prior year.
  • Gains from Sales and Divestitures was $1.2 million for Q3 2025 at Xtant Medical Holdings, up from $386624.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $1.5 million in Q4 2023 and troughed at $22245.0 in Q1 2023.
  • The 5-year median for Gains from Sales and Divestitures is $349572.0 (2021), against an average of $611811.6.
  • Year-over-year, Gains from Sales and Divestitures crashed 90.91% in 2023 and then surged 539.82% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $782596.0 in 2021, then skyrocketed by 91.72% to $1.5 million in 2022, then rose by 2.39% to $1.5 million in 2023, then dropped by 14.67% to $1.3 million in 2024, then decreased by 11.91% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Gains from Sales and Divestitures are $1.2 million (Q3 2025), $386624.0 (Q2 2025), and $44496.0 (Q1 2025).